LXEO
Lexeo Therapeutics Inc
NASDAQ · Biotechnology
$7.16
+0.27 (+3.92%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 110.56M | 98.68M | 97.87M |
| Net Income | 17.37M | 14.67M | 15.60M |
| EPS | — | — | — |
| Profit Margin | 15.7% | 14.9% | 15.9% |
| Rev Growth | +16.0% | -2.8% | +7.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 195.78M | 189.07M | 226.04M |
| Total Equity | 402.34M | 414.62M | 418.87M |
| D/E Ratio | 0.49 | 0.46 | 0.54 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 19.93M | 19.03M | 18.02M |
| Free Cash Flow | 11.85M | 8.63M | 11.57M |